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Novel Respiratory 
Syncytial Virus A 
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Germany,  
2011–2012
To the Editor: Respiratory syncy-
tial virus (RSV) is a major cause of se-
vere respiratory disease in infants and 
elderly persons. RSV strains have been 
divided into 2 major antigenic groups 
(A and B), which are further divided 
into several genotypes. The main ge-
netic and antigenic differences between 
genotypes are found within the 2 hy-
pervariable regions of the attachment 
(G) glycoprotein. In 1999, a novel RSV 
B genotype, which contained a 60-nt 
duplication in the second hypervariable 
region of the G protein, was discovered 
in Buenos Aires, Argentina, and named 
BA (1). Since then, genotype BA has 
almost completely replaced other RSV 
B strains worldwide and has diversified 
into several subgenotypes (2). 
In February 2012, as part of rou-
tine RSV surveillance, we identified 
a novel RSV A genotype with a 72-nt 
duplication in the second hypervari-
able region of G, thus representing the 
first RSV A genotype with nucleotide 
duplications in the G gene. Shortly 
thereafter, circulation of this genotype 
was reported in Ontario, Canada, in 
2010–11 and 2011–12, and the geno-
type was named ON1 (3). To investi-
gate the frequency of genotype ON1 
in Germany, we extended the molecu-
lar analysis of RSV strains from the 
previous 2 RSV seasons. The study 
was approved by the ethics committee 
of the medical faculty at the Univer-
sity of Würzburg, Germany.
From July 2010 through June 
2011 and from July 2011 through 
June 2012, we identified 271 and 181 
RSV-positive patients, respectively. 
Patients were identified from respira-
tory specimens sent by hospitals in 
Bavaria, Germany, for routine testing 
of respiratory viruses at the Institute 
of Virology and Immunobiology at the 
University of Würzburg. The mean 
age of all patients was 1.2 years (me-
dian 8.2 years; range 0.03–81.4 years), 
and 259 were male. Of the RSV-pos-
itive samples, 183 (67.5%) from sea-
son 2010–11 and 171 (94.5%) from 
season 2011–12 were analyzed by 
sequencing a fragment of ≈500 nt that 
encompassed the complete second hy-
pervariable region of the G gene (4). 
Alignment with reference sequences 
and phylogenetic analyses were con-
ducted by using MEGA 5.0 (5).
Molecular analysis of RSV-posi-
tive samples revealed that RSV A and 
B cocirculated during both seasons (98 
A and 85 B during 2010–11; 99 A and 
73 B during 2011–12). In accordance 
with previous reports (2), all RSV B 
strains from both seasons were identi-
fied as genotype BA. The novel RSV 
A genotype ON1 was not detected 
during 2010–11. However, 10 (10.1%) 
of 99 RSV A strains were assigned to 
genotype ON1 during 2011–12. All 
other RSV A strains of both seasons 
belonged to genotype GA2. An amino 
acid alignment of ON1 sequences is 
shown in the Figure. The duplication 
regions of 2 of the 10 ON1 strains 
contained 2-aa and 3-aa exchanges 
compared with the ON1 reference se-
quence (which has no exchanges) (3). 
Of note, an ON1 sequence from Japan 
with similar, partially even identical 
mutations was retrieved from Gen-
Bank (Figure). All mutations observed 
so far did not affect potential O-glyco-
sylation sites.
Of the 99 patients with RSV A 
infection diagnosed during 2011–12, 
a total of 91 were hospitalized chil-
dren. Genotype ON1 was identified in 
7 (25.0%) of 28 children in intensive 
care units (ICUs) and in 2 (3.2%) of 
63 children in other wards (p = 0.003, 
Fisher exact test). Children admit-
ted to an ICU were younger (me-
dian 0.2 years) than those not in an 
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Figure.	Amino	acid	sequence	alignment	of	the	second	hypervariable	region	of	the	respiratory	syncytial	virus	(RSV)	G	gene.	RSV	ON1	
sequences	and	RSV	A	reference	sequences	in	the	upper	part	of	the	alignment	are	designated	by	GenBank	numbers.	ON1	sequences	in	
the	lower	part	were	obtained	in	this	study	and	are	available	at	GenBank	under	accession	nos.	JX912355–JX912364.	Black	boxes	indicate	
the	duplicated	region;	black	circles	indicate	potential	O-glycosylation	sites;	and	gray	shading	indicates	potential	N-glycosylation	sites.	Dots	
indicate	nucleotide	identities,	dashes	indicate	adjustment	of	nucleotide	insertions,	and	asterisks	indicate	stop	codons.	WUE,	Würzburg.
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ICU (median age 1.2 years; p<0.001, 
Mann-Whitney U test). An explor-
atory logistic regression analysis on 
ICU admittance, adjusted for age, 
confirmed a strong association be-
tween RSV genotype ON1 and ICU 
admittance (adjusted odds ratio 8.4; 
95% CI 1.5%–46.6%; p = 0.015). 
However, this significant difference 
should be interpreted with caution for 
2 reasons: 1) samples from patients in 
wards other than an ICU originated 
mainly in the Würzburg area, whereas 
samples from patients in ICUs were 
received from pediatric hospitals in 
various regions of Bavaria; 2) clinical 
information on patients not in ICUs 
was not available for assessment of 
whether the difference persisted when 
taking into account other risk factors 
for severe RSV disease.
In summary, the novel RSV A 
genotype ON1 containing a 72-nt du-
plication in the G gene was not found 
during 2010–11, but it constituted al-
ready 10.1% of all RSV A strains in a 
patient cohort from Bavaria, Germa-
ny, in the next season, 2011–12. In the 
context of the primary report of ON1 
in Ontario, Canada (3), and the Gen-
Bank entry from Japan, our data sug-
gest worldwide emergence of ON1. 
The almost complete worldwide 
replacement of circulating RSV B 
genotypes with the BA strain contain-
ing a comparable 60-nt duplication, 
which began in 1999, suggests that 
these duplications provide a selective 
advantage (2). Thus, molecular analy-
sis of circulating RSV strains should 
be continued to determine whether 
ON1 has the potential to replace other 
RSV A strains in the years to come as 
did RSV B genotype BA during the 
past decade.
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Travel-related  
Neisseria  
meningitidis  
Serogroup W135 
Infection, France
To the Editor: A multinational 
outbreak of infection with Neisseria 
meningitidis serogroup W135 belong-
ing to the sequence type (ST) 11 clon-
al complex started in the year 2000 
among pilgrims to Mecca, Saudi Ara-
bia, and their contacts and continued 
in 2001 in countries of sub-Saharan 
Africa (primarily Burkina Faso) (1). 
Thereafter, infection caused by these 
isolates decreased (2), but quadriva-
lent meningococcal vaccine (against 
serogroups A, C, Y, and W135) was 
recommended for pilgrims and travel-
ers to countries in the meningitis belt 
of Africa, which spans sub-Saharan 
Africa from Ethiopia to Senegal. After 
2001, infections caused by serogroup 
A predominated in the meningitis 
belt, but isolates of serogroup X also 
emerged (3); isolates of serogroup 
W135/ST11 increased again in Niger 
in 2010 (4). 
During January 1–March 11, 
2012, >4,000 suspected cases of me-
ningococcal disease caused mainly 
by serogroup W135 were reported in 
countries of the African meningitis 
belt, including Benin, Burkina Faso, 
Mali, and Côte d’Ivoire (5). We pres-
ent extensive bacteriologic and mo-
lecular characterization of N. menin-
gitidis W135 isolates from 6 patients 
with meningococcal disease reported 
in France since January 2012; we also 
present typing data from 8 cases of 
meningitis in Côte d’Ivoire. None of 
the patients had received meningococ-
cal vaccine. 
The cases in France were neither 
epidemiologically nor geographically 
linked; 4 were in residents of the Paris 
region. All cases were linked to recent 
travel to sub-Saharan Africa by the 
patient or patient contacts; 4 patients 
reported recent travel to Benin, Sene-
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